People In Brief
This article was originally published in The Gray Sheet
FDA's Goodman named acting chief medical officer: Jesse Goodman is serving as FDA's acting chief medical officer as the agency management realigns to prepare for the new administration's topside leadership team. Goodman, director of the Center for Biologics Evaluation & Research since 2002, was detailed to the CMO post the week of March 9, FDA said. CBER Deputy Director Karen Midthun is now running the biologics center. A virologist by training, Goodman joined FDA in 1998 to direct the interagency task force on antimicrobial resistance. He later moved into CBER, where his work on bioterrorism preparedness brought him into the same orbit as FDA Commissioner-nominee Margaret Hamburg. The two served on several Institute of Medicine panels focused on microbial threats and bioterrorism preparedness in 2002 and 2003. Goodman was also selected as FDA's lone representative on the Federal Coordinating Committee on Comparative Effectiveness Research, appointed by the Department of Health and Human Services March 19
You may also be interested in...
House and Senate Democrats sponsor legislation to authorize FTC enforcement against sales of "consumer goods and services at an unconscionably excessive price during the" COVID-19 pandemic. "It’s outrageous that some companies and individuals are taking advantage of consumers by price-gouging," says Energy and Commerce Committee Chairman Frank Pallone.
Robert Califf, a former FDA commissioner turned Verily Life Sciences exec, is just one of the voice predicting a long-term impact on clinical trial processes from the COVID-19 outbreak.
A US National Academies meeting on digital health technology showcased the communication gap between regulators and tech developers when it comes to important concepts like “digital biomarkers.”